Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683678 · ClinicalTrials.gov registry record
US Selumetinib Registry
A clinical trial, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- 37
- Enrollment target
NCT05683678 is a clinical trial that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT05683678 was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to understand treatment patterns and assess long-term effectiveness and safety outcomes associated with selumetinib treatment as well as to explore clinical and non-clinical factors affecting those outcomes in patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs) who started selumetinib between the ages of 2 to 18 years inclusive, and initiated selumetinib treatment on or after 10 April 2020 in a real-world setting.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-01-04 |
| Est. Completion | 2024-11-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05683678
The ClinicalTrials.gov registry entry for NCT05683678 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05683678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05683678 about?
NCT05683678 is a clinical study titled "US Selumetinib Registry". The purpose of this study is to understand treatment patterns and assess long-term effectiveness and safety outcomes associated with selumetinib treatment as well as to explore clinical and non-clinical factors affecting those outcomes in patients with neurofibromatosis type 1 (NF1) and plexiform ne...
What is the current status of trial NCT05683678?
This trial is currently terminated. The enrollment target is 37 participants. The study started on 2019-01-04. Estimated completion is 2024-11-13.
Who is sponsoring clinical trial NCT05683678?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.